Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firdapse in Congenital Myasthenic Syndromes
NCT02562066Phase 3Completed
- Start
- Jan 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amifampridine in congenital myasthenic syndromes (CMS) (2 arms). Primary endpoint: Subject Global Impression at Day 29. Started Jan 2016; status: completed.
02
Drugs
amifampridine
03
Conditions
congenital myasthenic syndromes (CMS)
Beyond the preview
Go deeper on NCT02562066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562066.